SCHEMBL2261155

SCHEMBL2261155

Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(c3cccc(S(C)(=O)=O)c3)CC2)ncc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.43
CDK2 P24941 4/20 0.42
CCNE1 P24864 3/20 0.42
CDK7 P50613 2/20 0.42
CCNH P51946 2/20 0.42
MNAT1 P51948 2/20 0.42
CCNT1 O60563 1/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
CCNB1 P14635 1/20 0.42
CCND1 P24385 1/20 0.42
CCND3 P30281 1/20 0.42
CDK9 P50750 1/20 0.42
CDK6 Q00534 1/20 0.42
PTK2 Q05397 7/20 0.41
NR1H2 P55055 4/20 0.40
NR1H3 Q13133 4/20 0.40
KDR P35968 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263677 0.90 KCNH2 (0.45) KCNH2CDK2CDK1CDK4CCND1
SCHEMBL2263668 0.89 KCNH2 (0.46) KCNH2CDK4NR1H2NR1H3CYP2C9
SCHEMBL2259866 0.89 KCNH2 (0.47) KCNH2CDK2CCNE1CDK7CCNH
SCHEMBL2262210 0.87 KCNH2 (0.54) KCNH2PTK2CYP2C9
SCHEMBL2261644 0.84 KCNH2 (0.43) KCNH2CDK2CCNE1CDK7CCNH
SCHEMBL2265459 0.83 KCNH2 (0.41) KCNH2NR1H2NR1H3CYP2C9
SCHEMBL2262093 0.83 KCNH2 (0.51) KCNH2CDK2CDK1PTK2KDR
SCHEMBL2260498 0.82 KCNH2 (0.51) KCNH2CDK2CCNE1CDK7CCNH
SCHEMBL2262219 0.79 KCNH2 (0.44) KCNH2PTK2CYP2C9
SCHEMBL2260009 0.79 KCNH2 (0.39) KCNH2CDK2CCNE1CDK7CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP claimed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US claimed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A KCNH2 4033/4885CDK2 260/4885CCNE1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.